Market Tracker

10/23 3:50am ET

Intercept Pharmaceuticals Inc (NASDAQ:ICPT)

66.85
Delayed Data
As of Oct 20
 -0.01 / -0.01%
Today’s Change
54.98
Today|||52-Week Range
141.00
-38.47%
Year-to-Date
Bristol-Myers (BMY), TARGET Extend Partnership for NASH Study
Oct 13 / Zacks.com - Paid Partner Content
Non-Alcoholic Steatohepatitis 2017 Progress Update
Oct 12 / Zacks.com - Paid Partner Content
Here's Why Intercept (ICPT) Stock Lost 37% So Far in 2017
Oct 12 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close66.86
Today’s open67.47
Day’s range64.80 - 67.59
Volume1,565,575
Average volume (3 months)1,181,289
Market cap$1.7B
Dividend yield--
Data as of 3:59pm ET, 10/20/2017

Growth & Valuation

Earnings growth (last year)-75.10%
Earnings growth (this year)+16.78%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)+796.87%
P/E ratioNM
Price/Sales107.40
Price/Book5.27

Competitors

 Today’s
change
Today’s
% change
MDCOMedicines Co-0.47-1.36%
AGIOAgios Pharmaceutical...-1.48-2.15%
SAGESAGE Therapeutics In...+0.58+0.92%
PBHPrestige Brands Hold...+0.11+0.23%
Data as of 3:59pm ET, 10/20/2017

Financials

Next reporting dateNovember 15, 2017
EPS forecast (this quarter)-$3.44
Annual revenue (last year)$25.0M
Annual profit (last year)-$412.8M
Net profit margin-1,654.56%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
President, Chief Executive Officer &
Director
Mark E. Pruzanski
Chief Operating Officer
Jerome B. Durso
Corporate headquarters
New York, New York

Forecasts